Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TAK-360 by Takeda Pharmaceutical for Idiopathic Hypersomnia (IH): Likelihood of Approval
TAK-360 is under clinical development by Takeda Pharmaceutical and currently in Phase I for Idiopathic Hypersomnia (IH). According to GlobalData,...
Data Insights
TAK-360 by Takeda Pharmaceutical for Type 2 Narcolepsy (Narcolepsy without Cataplexy): Likelihood of Approval
TAK-360 is under clinical development by Takeda Pharmaceutical and currently in Phase I for Type 2 Narcolepsy (Narcolepsy without Cataplexy)....